														10	MS	FC	PRIV
SUSPECT ADVERSE REACTION REPORT														—			
SUSPE	CT ADVERSE F	REACTION REPO	RT														
														П		T	
													Ш	\perp			
I. REACTION INFORMATION																	
1. PATIENT INITIALS	1a. COUNTRY	2. DATE OF BIRTH	2a. AGE	3. SEX	3a. WEIGHT	1	-6 RE	ACTION	ONSE	ΞT	8-12		ECK A				
(first, last) PRIVACY	DOMINICAN REPUBLIC	Day Month Year PRIVACY	12	Male	Unk	Day	у	Month Unk		Year	1		PROP VERSI		E TO ACTIO	N	
			Years	iviale				Ulik			ļ						
7 + 13 DESCRIBE REAC Event Verbatim [LOWER	(+ 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas) PATIENT DIED																
when I do the needle change procedure and the movement as the nurse informed me, I give the first touch for								INVOLVED OR									
issue]	him to discard the drop, and then it shows the numbering that show me more than the amount [Device use issue]																
	setting the numbers on the device was getting a bit hard (it was not light). [Device difficult to use]																
I should apply and the cartridge where the medication goes came loose/disconnected (where I put the needle), so I can put it [Device connection loose]										╽┖	OR	SIGN	IIFIC#	NT	ENI		
when they tried to	o dial 0.4 mg it did r	not dial [Device mechai	,	-									CAPAC				
when they tried to dial 0.4 mg it did not dial [Resistance to movement in																	
				(Conti	nued on Ad	dition	al Inf	ormati	ion P	age)	[LIFI THE	E REATE	ENIN	3		
· · · · · · · · · · · · · · · · · · ·																	
14 SUSPECT DRUGGS	II. SUSPECT DRUG(S) INFORMATION 14. SUSPECT DRUG(S) (include generic name) 20. DID REACTION																
		Solution for injection {Lot	t # HL202	24; Exp.Dt.	15-JUL-20	26}					A		AFTE		OPPIN	G	
#2) Genotropin Pe	en (SOMATROPIN (I	DEVICE CONSTITUENT	Γ)) Solutio	on (Conti	nued on Ad	dition	al Inf	ormati	ion P	age)]						
15. DAILY DOSE(S) #1) 1.6 mg, daily				16. ROUTE(S) # 1) Unkn o	OF ADMINIST	RATIO	N				Ιr	YE	s \sqsubset	NO	M۱	NA	
#2)				#2) Unkno										_			
17. INDICATION(S) FOR #1) Unknown	RUSE										R	ID REA	EAR A	AFTE			
#2) Unknown											R	REINTF	₹ODU	CTIO	N?		
18. THERAPY DATES(from/to) 19. THERAPY D											٦	T YE	s \sqsubset	1 NO	M۱	JA	
#1) Unknown #2) Unknown				,	1) Unknown 2) Unknown						° <u>Г</u>	1.10	Z	•/ (
III. CONCOMITANT DRUG(S) AND HISTORY																	
22 CONCOMITANT DRI	IIG(S) AND DATES OF ADM	III. CONCOMI) AND H	151	<u>UR</u>	Y									
22. CONCOMITANT DIC	OO(O) AND DATES OF ADM	mid Traffor (exclude mose us	sed to treat re	eactions													
00 OTHER RELEVANT	LUCTORY (s. s. diseasestics	-11	416	-1 -4- \										_			
From/To Dates	HISTORT. (e.g. diagnostics,	allergies, pregnancy with last mo Type of History / Notes	onth of perior	Description													
Unknown																	
		IV. MANUF	ACTU	RER INF	ORMAT	TION	١										
	IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER 26. REMARKS																
Laura Arce Mora																	
Avenida Escazú, T San Jose, COST																	
,																	
	04 455 00	NITROL NO		05' 1''	ME AND ADD	2500)F 55	00075						_			
	24b. MFR CO				ME AND ADDF AND ADD												
		00012659			: AND ADD												
24c. DATE RECEIVED BY MANUFACTURE	ER 24d. REPORT	SOURCE LITERATURE					_										
05-APR-2025	I NAME AND ADDRESS WITHHE																
DATE OF THIS REPORT				— NAME	: AND ADD	RES	S WI	THHE	:LD.								
09-APR-2025	INITIAL	FOLLOWUP:	2														

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

device]

Case Description: This is a spontaneous report received from a Consumer or other non HCP and Nurses from product quality group, Program ID: 164974.

A 12-year-old male patient received somatropin (GENOTROPIN PEN), first regimen (Lot number: HL2024, Expiration Date: 15Jul2026) at 1.6 mg daily and second regimen (Batch/Lot number: unknown) at 1 mg daily, Device Expiration Date: 31Dec2026. The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: DEVICE USE ISSUE (non-serious), described as "when I do the needle change procedure and the movement as the nurse informed me, I give the first touch for him to discard the drop, and then it shows the numbering that show me more than the amount"; DEVICE DIFFICULT TO USE (non-serious), described as "setting the numbers on the device was getting a bit hard (it was not light)."; DEVICE CONNECTION ISSUE (non-serious), described as "I should apply and the cartridge where the medication goes came loose/disconnected (where I put the needle), so I can put it"; DEVICE MECHANICAL ISSUE (non-serious), DEVICE PHYSICAL PROPERTY ISSUE (non-serious) and all described as "when they tried to dial 0.4 mg it did not dial". The action taken for somatropin was unknown.

Causality for "when i do the needle change procedure and the movement as the nurse informed me, i give the first touch for him to discard the drop, and then it shows the numbering that show me more than the amount", "setting the numbers on the device was getting a bit hard (it was not light).", "i should apply and the cartridge where the medication goes came loose/disconnected (where i put the needle), so i can put it" and "when they tried to dial 0.4 mg it did not dial" was determined associated to device constituent of somatropin (malfunction).

Product Quality Group provided investigational results on 26Feb2025 for somatropin (device constituent): Site investigation (Pfizer Manufacturing site): No further investigation was required as no valid lot number or returned sample was available. This complaint will continue to be trended. If additional information becomes available, this complaint will be reopened. Device investigation: This investigation is based on the information captured in the Complaint Description and Argus Report. The Complaint Issue, Cartridge/Holder Loose, was reported. The Risk Management File was reviewed to confirm that the Hazard(s) and Hazardous Situation(s) associated with the Complaint Issue are documented in the Hazard Analysis (INX100281795), Version (9.0). All complaint investigations are trended. There is no current trend alert documented.

Product Quality Group provided investigational results on 31Mar2025 for somatropin (device constituent): MDCP Investigation Summary and Conclusion: This complaint for The patient assistant says, "I need someone to help me, when I do the needle change procedure and the movement as the nurse informed me, I give the first touch for him to discard the drop, and then it shows the numbering that show me more than the amount I should apply and the cartridge where the medication goes came loose/disconnected (where I put the needle), so I can put it. for Genotropin/Genotonorm U2 Pen was investigated by the manufacturing site.

Additional information: As of 03Apr2025, reporter stated they finished setting the device and when they tried to dial 0.4 mg it did not dial, also stated that when setting the numbers on the device was getting a bit hard (it was not light). As of 05Apr2025, nurse reported that the patient's mother complaint about the pen's button not working properly, but nurse stated this was not true as she checked it and everything was working normally, it was just a bit hard to press the button but it was normal.

Follow-up (26Feb2025): This is a spontaneous follow-up report received from product quality group. Updated information: investigation results.

Follow-up (19Mar2025): Follow-up attempts are completed.

Follow-up (31Mar2025): This is a follow-up report from the product quality group. Updated information included: investigation results, action taken and expiration date.

Follow-up (03Apr2025): This is a spontaneous follow-up report received from a Consumer or other non-HCP, Program ID: (164974). Updated information includes new events of device mechanical issue, device physical property issue and device difficult to use.

Follow-up (05Apr2025): This is a spontaneous follow-up report received from a Nurse, Program ID: (164974). Updated information: Dosage regimen, Device expiration date, clinical course.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Genotropin Pen (SOMATROPIN) Solution for injection; Regimen #2	1 mg, daily; Unknown	Unknown	Unknown; Unknown
#2) Genotropin Pen (SOMATROPIN (DEVICE	; Unknown	Unknown	Unknown;

Unknown

ADDITIONAL INFORMATION

14-19. SUSPECT DRUG(S) continued

15. DAILY DOSE(S);
14. SUSPECT DRUG(S) (include generic name)
15. DAILY DOSE(S);
16. ROUTE(S) OF ADMIN
17. INDICATION(S) FOR USE
18. THERAPY DATES (from/to);
19. THERAPY DURATION

CONSTITUENT)) Solution for injection;

Regimen #1